Similar articles

• HER2 status and benefit from adjuvant trastuzumab in breast cancer.

  Paik S, Kim C, Wolmark N. Paik S, et al. N Engl J Med. 2008 Mar 27;358(13):1409-11. doi: 10.1056/NEJMc0801440. N Engl J Med. 2008. PMID: 18367751 No abstract available.
• Trastuzumab (herceptin) for early-stage breast cancer.

  Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M. Ismael G, et al. Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. doi: 10.1016/j.hoc.2007.03.003. Hematol Oncol Clin North Am. 2007. PMID: 17512447 Review.
• Controversies in the use of adjuvant trastuzumab (Herceptin).

  Chowdhury S, Pickering L, Ellis P. Chowdhury S, et al. J Br Menopause Soc. 2006 Dec;12(4):172-4. doi: 10.1258/136218006779160517. J Br Menopause Soc. 2006. PMID: 17178019 Review.
• [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].

  Mallmann P. Mallmann P. Internist (Berl). 2006 Nov;47(11):1183-5. doi: 10.1007/s00108-006-1720-x. Internist (Berl). 2006. PMID: 17048017 German. No abstract available.
• [Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients].

  Zhou NN, Teng XY, Liu DG, Xu R, Guan ZZ. Zhou NN, et al. Ai Zheng. 2008 Dec;27(12):1307-9. Ai Zheng. 2008. PMID: 19079999 Clinical Trial. Chinese.